Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target

Benzinga · 05/28 12:22
Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 price target.